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Investigation of differences between primary studies
As previous studies probably overestimated the likelihood of hospitalisation, the authors adjusted the risk of complications to bias the analysis toward liver biopsy. The authors assumed that a short-term response only, or the absence of a response, conveys no long-term benefits, even if this does not conform with the results of previous studies. If improvement does lead to improved prognosis, then this assumption biases against interferon treatment.
Results of the review
The prognosis following decompensation depended on the mode of presentation: diuretic-sensitive ascites, diureticrefractory ascites, variceal hemorrhage, and hepatic encephalopathy. The odds ratio (OR) for mild or moderate hepatitis biopsy findings was 4.94 (p=0.16), the OR for HCV RNA viral load of no more than 3.5x10?5 was 17.8, the OR for HCV RNA viral load of more than 3.5x10?5 and no more than 32x10?5 was 3.24 (p<0.001), and the OR for genotype 3a was 29.7 and for genotype not 1b or 3a was 8.20 (p<0.001). Whilst the review suggested a risk of hospitalisation of 4.7% (95%CI: 0 -17.1%), the authors, in order to bias the review toward liver biopsy, adopted a value of 0.3% as the risk of complications. A mortality risk of 0.018% or 18 deaths per 100,000 liver biopsies was found. The proportion of the population who would be treated varied between 0% and 100%. The sustained response to interferon would range from 7.9% for empirical treatment of all patients to 23% for highly selective pre-treatment strategies.
The probability of sustained response among all patients varied between 0% and 7.9%, and among patients treated varied between 0% and 23.3%. More selective strategies have a lower number of patients needed to treat with interferon to achieve 1 sustained response. In general, this number ranged from 4.5 to 12.6. But these selective strategies also withhold treatment from 36% to 85% of patients who could have had a sustained response if treated. This number of patients ranged from 0% to 100%. The model estimated that treatment of all patients with CHC would reduce their lifetime incidence of cirrhosis from 66% to 60%, of decompensated cirrhosis from 46% to 43%, of hepatocellular carcinoma from 18% to 17%, and of liver transplantation from 6.3% to 5.9%. It also estimated that
